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Abstract
Objectives
Observationally, testosterone is negatively associated with systemic inflammation, but this
association is open to both residual confounding and reverse causality. Large-scale randomized controlled trials (RCTs), assessing exogenous effects, are presently unavailable.
We examined the association of endogenous testosterone with well-established systemic
inflammatory markers (white blood cell, granulocyte, lymphocyte and high-sensitivity C-reactive protein (hsCRP)) using a separate-sample Mendelian randomization analysis to minimize reverse causality.

Methods
A genetic prediction rule for serum testosterone was developed in 289 young Chinese men
with mean age of 21.0, using selected testosterone-related SNPs (rs10046, rs1008805 and
rs1256031). Multivariable linear regression was used to examine the association of genetically predicted serum testosterone with inflammatory markers among 4,212 older Chinese
men from the Guangzhou Biobank Cohort Study.

Results
Genetically predicted testosterone was unrelated to white blood cell count (-0.01 109/L per
nmol/L testosterone, 95% confidence interval (CI) -0.05 to 0.04), granulocyte count (-0.02
109/L, 95% CI -0.06 to 0.02), lymphocyte count (0.005 109/L, 95% CI -0.01 to 0.02) and
hsCRP (-0.05 mg/L, 95% CI -0.15 to 0.06).
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Conclusion
Our findings did not corroborate any anti-inflammatory effects of testosterone or corresponding potentially protective effects of testosterone on chronic diseases resulting from reduced low-grade systemic inflammation.

Introduction
Inflammation is an important component of major non-communicable diseases, such as cardiovascular disease (CVD) and diabetes [1]. The low-grade systemic inflammation characterizing CVD and other chronic diseases is not well understood, but appears to be a state of
immune dysregulation or dysfunction [1]. Since the 1920s, when testicular extracts were first
developed, androgens have been known to affect aspects of the immune system in animals
[2,3]. White blood cell (WBC) count and high-sensitivity C-reactive protein (hsCRP) are wellestablished markers of systemic inflammation and also predictive for CVD mortality [4,5].
Most, but not all, observational studies report testosterone inversely associated with C-reactive
protein (CRP) [6,7] and WBC and/or its differentials [8,9]. However, these study designs are
open to residual confounding and reverse causality [10] arising from testosterone falling with
age and the effects of ill-health [11,12]. Small-scale randomized controlled trials (RCTs), designed to assess other outcomes, generally report no effect of testosterone administration on
CRP [13–15] or WBC [16], although one RCT among hypogonadal men with metabolic syndrome found testosterone decreased CRP [16]. To our knowledge, there is no material evidence
from meta-analysis of RCTs or large-scale RCTs.
A Mendelian randomization (MR) design, using testosterone related genetic variants as an
instrumental variable, provides a means of assessing the causal effect of testosterone on markers of systemic inflammation without any intervention. Genetic variants, resulting in life-long
differences in endogenous exposures, are determined at conception, and so are unlikely to be
associated with socioeconomic position or other confounders. Genetic polymorphisms affect
testosterone [17], making an MR design feasible. Using an MR analysis with a separate-sample
instrumental variable (SSIV) estimator, we examined the association of testosterone in early
adulthood, when testosterone levels are at their lifetime peak, with well-established markers of
systemic inflammation among men.

Materials and Methods
Study design
This study uses a separate-sample two-stage MR analysis. First, a genetic prediction rule for
serum testosterone was developed in young Chinese men from Hong Kong, as described previously [18]. Second, the association of genetically predicted testosterone with WBC, lymphocyte
and granulocyte counts and hsCRP among older Chinese men from the Guangzhou Biobank
Cohort Study (GBCS) was examined [19].

Sources of data
To generate a genetic prediction rule for testosterone, a sample of young men with parents and
at least three grandparents born in Hong Kong or Guangdong province was recruited, but restricted to those not taking any medication potentially affecting testosterone. Morning blood
samples were taken for testosterone assessment and DNA extraction. Testosterone was assessed
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by competitive immunoassay on Vitros 3600 immunodiagnostic system (Ortho Clinical Diagnostics Inc, USA) with a detection limit of 0.17 nmol/L. Calibrators for this assay were in-house
reference materials from Ortho Clinical Diagnostics that were value-assigned to correlate to
samples measured by isotope-dilution gas chromatography-mass spectroscopy (ID-GC/MS).
The intra- and inter-assay coefficients of variation (CVs) were 4.9% and 5.7% at 4.4 nmol/L,
3.2% and 3.9% at 16.3 nmol/L, and 1.8% and 3.0% at 37.5 nmol/L, respectively. DNA was extracted and analyzed at the Centre for Genomic Sciences of the University of Hong Kong for selected SNPs, selected as shown in S1 Fig, including SNPs from ESR1 (rs722208 and rs2175898),
CYP19A1 (rs10046 and rs1008805) and ESR2 (rs1256030 and rs1256031) using a Mass ARRAY
system (Sequenom, San Diego, California), as described previously [18]. For DNA quality analysis we used spectrophotometry for most of the samples and gel electrophoresis for 4 duplicate
check controls and 6 randomly selected samples in each DNA sample plate. The determined
sample concentration and A260/280 ratios were 10–20 ng/μL and 1.7–2.0 respectively. A call
rate <80% was considered failure. All the SNPs passed with a call rate >95%. A self-administered questionnaire was used to collect socioeconomic position and health status.
To examine the association of genetically predicted testosterone with markers of inflammation, we used a large sample of older men (50+ years) from GBCS. GBCS is an ongoing collaboration of Guangzhou Number 12 Hospital, the Universities of Hong Kong and Birmingham,
UK, as described elsewhere [19]. All participants were permanent residents of Guangzhou and
members of the “The Guangzhou Health and Happiness Association for the Respectable Elders” (GHHARE), a community social and welfare association unofficially aligned with the
municipal government. Membership is open to older people for a monthly fee of 4 Yuan (50
US cents). Recruitment occurred in 3 phases: phase 1 from September 2003 to November 2004,
phase 2 from April 2005 to May 2006, and phase 3 from September 2006 to January 2008. Follow-up of the participants started in 2008. About 7% of permanent Guangzhou residents aged
50+ years are members of GHHARE, of whom 11% (about 10,000 participants) enrolled for
each of phases one, two and three. Inclusion criteria were that they were capable of consenting,
that they were ambulatory, and that they were not receiving treatment modalities which if
omitted may result in immediate life threatening risk, such as chemotherapy or radiotherapy
for cancer, or dialysis for renal failure. Fasting blood samples were collected at recruitment in
phase 3 and at follow-up for participants recruited in other phases. Samples were stored, as
whole blood or as buffy coat and sera, at -80°C [19] for all apart from a subset of phase 3 participants whose DNA was extracted from fresh blood and stored at -80°C [20]. The detailed methods of measurement have been reported previously [19,21,22]. Quantitative haematological
analysis was performed using a SYSMEX KX-21 haematology analyser, from which white
blood cell count, lymphocyte cell count and granulocyte cell count were available. HsCRP was
determined by the Shimadzu CL-8000 Clinical Chemical Analyser (Shimadzu Corp, Kyoto,
Japan) in the hospital laboratory. Selected SNPs were analyzed by a commercial company (Beijing CapitalBio Corporation) in Beijing using a Mass ARRAY system (Sequenom, San Diego,
California). Any measurement error is likely to be non-differential, which is compensated for
by our large sample size. The University of Hong Kong-Hospital Authority Hong Kong West
Cluster Joint Institutional Review Board approved the study. The Guangzhou Medical Ethics
Committee of the Chinese Medical Association approved GBCS, including the use of genetic
data, and all participants gave written, informed consent prior to participation.

Exposure
The primary exposure was genetically predicted testosterone. Genetically predicted log testosterone was obtained from stepwise regression of all selected SNPs on testosterone in the sample
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of young men, which gave predicted log testosterone as -0.07×rs1008805+0.07×rs100460.07×rs1256031+3.0, as in S1 Table and as reported previously [18]. The F-statistic was 13.3,
suggesting a reliable genetic instrument, because an F-statistic>10 suggests a reliable genetic
instrument [23]. The proportion of variance in log testosterone explained by the genetic prediction rule was 4.1%, which is typical for MR studies [20]. Higher genetically predicted log testosterone was associated with higher log serum testosterone. Genetically predicted testosterone
was estimated as the anti-log of genetically predicted log testosterone. Testosterone, instead of
log testosterone, was used as the exposure for ease of interpretation as they both gave the same
pattern of results.

Outcomes
The primary outcomes were inflammatory markers including WBC count, lymphocyte cell
count, granulocyte cell count and hsCRP.

Statistical analysis
We used an SSIV estimate from two separate samples [24]. ANOVA was used to compare genetically predicted testosterone by key characteristics. Multivariable linear regression was used
to assess the association of genetically predicted testosterone with markers of systemic inflammation. Power calculation was conducted using the formulas in the study of Freeman et al.
[25], and compared with the simulation results in the study of Pierce et al [26]. All statistical
analyses were conducted using Stata 10.1 (StataCorp LP, College Station, Texas).

Results
Among the 8,450 men in all 3 phases of GBCS, DNA for SNP testing was available for 4,262
men; availability depended on recruitment phase and other logistical concerns, but not on inflammatory status. Among the 4,262 men, 4,212 (98.8%) had complete information on the selected SNPs. However, hsCRP was only measured in phase 1 and was only available for
1,636 men.
Table 1 shows, as expected, genetically predicted testosterone among the older men was not
associated with age, education, smoking and use of alcohol. Genetically predicted testosterone
(mean = 18.0 nmol/L, standard deviation = 1.2 nmol/L) does not capture variation due
to confounders.
Table 2 shows genetically predicted testosterone among the older men was not associated
with markers of systemic inflammation. The estimates were close to the null.

Discussion
Using a separate-sample MR analysis in Chinese men, we found no association of endogenous
testosterone with markers of systemic inflammation. Our novel study provides no support for
any anti-inflammatory effects of testosterone on hsCRP, WBC or its differentials, although we
cannot preclude possible effects of testosterone for other inflammatory markers. Our study
from China also adds to the limited findings from developing countries in contrast to most previous studies from developed countries.
To our knowledge, this is the first study to use an MR design, with an SSIV estimator, to
provide an unbiased estimate of the effects of genetically predicted testosterone on systemic inflammation. In cross-sectional studies, it is difficult to determine causal direction because some
markers of systemic inflammation, such as pro-inflammatory cytokines, inhibit testosterone
secretion through their influence on the hypothalamic-pituitary-gonadotropic axis [27].
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Table 1. Genetically Predicted Testosterone by Socio-demographic Characteristics Among 4,212 Men (50+), Guangzhou Biobank Cohort Study,
2003–2008.
Characteristic

Age group, years

No.

%

Genetically predicted testosterone (nmol/L)
Mean

SD

4212

0.94

50–54

8.1

18.05

1.10

55–59

20.2

18.01

1.22

60–64

25.4

18.01

1.24

65–69

24.1

18.01

1.27

70–74

16.5

17.99

1.19

75–79

4.2

17.95

1.28

80

1.5

18.15

1.52

2.6

18.11

1.36

Education

4209

Less than primary school

0.91

Primary school

26.9

18.01

1.22

Junior middle school

30.0

18.01

1.19

Senior middle school

24.2

18.01

1.23

8.9

17.99

1.34

7.4

17.96

1.24

40.8

17.99

1.22

Junior college
College
Smoking status

4192

Never smoker

0.59

Ex-smoker

27.9

18.02

1.25

Current smoker

31.3

18.03

1.22

Never

51.8

18.02

1.25

<1/month

19.9

18.03

1.19

<1/week

4.3

18.04

1.20

1-4/week

6.0

18.03

1.30

5+/week

11.9

17.90

1.19

Ex-drinker

4.4

18.01

1.20

Unknown

1.8

18.08

1.27

Use of alcohol

ANOVA p valuea

4212

0.49

Abbreviation: SD, standard deviation
a

Genetically predicted testosterone was not associated with age, socioeconomic position (education) or lifestyle, including smoking status and use of
alcohol (ANOVA p value>0.05).
doi:10.1371/journal.pone.0126442.t001

However, our study using genetically predicted testosterone in early adulthood minimizes such
reverse causality and provides stronger evidence with minimal confounding. Compared with
traditional IV analysis, SSIV is more useful and cost-efficient when the phenotype of interest is
either not measured or is measured with substantial error in the sample with the outcome
[24,28]. Simulations have shown SSIV is preferable to using the same sample for assessing the
relations of instrument to exposure and instrument to outcome [29]. The SSIV design also
makes it feasible to use testosterone in early adulthood as a marker of lifetime exposure when it
is infeasible to obtain lifetime sex hormones for the older people, because it would require measurements from the 1960s. SSIV remediates weak-instruments bias and reduces concerns
about using multiple polymorphisms as IVs [24]. In addition, any correlation of the genetic
variants with unmeasured confounders in the sample with the phenotype is unlikely to be replicated in the sample with the outcome due to the different data structures [24].
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Table 2. Effect of genetically predicted testosterone on markers of systemic inflammation among
4182 and a subgroup of 1636 men (50+) in a Mendelian randomization study design, Guangzhou Biobank Cohort Study, 2003–2008.
Outcome

n

Beta coefﬁcienta

95% CI

WBC Count

4180

-0.01

-0.05 to 0.04

4167

-0.02

-0.06 to 0.02

(109/L)
Granulocyte
(109/L)
Lymphocyte

4182

0.005

-0.01 to 0.02

9

(10 /L)
hsCRP (mg/L)

1636

-0.05

-0.15 to 0.06

a

Beta coefﬁcient refers to the average change in white blood cell and its differentials counts and hsCRP

level with each unit (nmol/L) increase in genetically predicted testosterone.
doi:10.1371/journal.pone.0126442.t002

Our findings are consistent with most RCTs reporting no significant effects of testosterone
therapy on markers of systemic inflammation [13–16]. Our results are less consistent with observational studies [6–9], where testosterone tends to be negatively associated with markers of
systemic inflammation. This study does not corroborate predictions from an evolutionary biology perspective, where androgens might be expected to be positively associated with systemic
inflammatory markers as a reflection of their immunosuppressive role [30]. Several possible explanations exist. First, serum testosterone may reflect androgen production more than androgen activity. Successful use of anti-androgens at castrate levels of serum testosterone in
prostate cancer trials has challenged the extent to which serum testosterone reflects androgen
activity [31]. Serum testosterone is only weakly correlated with the final metabolite of all androgens [32,33]. Second, androgens may be positively related with other markers of systemic
inflammation, such as soluble IL-6 and TNF-alpha. However, hsCRP is closely correlated with
IL-6 and TNF-alpha, and gives consistent associations with CVD risk factors [34].
Although we used an MR analysis design with similar properties to an RCT [10], limitations
exist. First, two independent samples were used and genetic associations derived from one sample might not apply to the other. However, the two samples had the same genetic origin, because residents of Hong Kong and Guangzhou (the capital of Guangdong province) share a
recent, common ancestry, as the Hong Kong population was largely formed by migration from
Guangdong province in the late 1940s and early 1950s [35]. We restricted the sample of young
men to those with both parents and at least 3 grandparents born in Hong Kong or Guangdong
province to ensure genetic homogeneity, reflected by the similar allele frequencies of the genetic variants in the two samples [18]. Moreover, it is generally assumed in genetic studies that a
gene (and hence) a genetic score has the same effect on the phenotype across time and space.
In the same study, genetically predicted testosterone had the expected negative relation with
HDL-cholesterol [18], of the expected order of magnitude [36], also suggesting some validity.
Second, the effect of testosterone on markers of systemic inflammation might be confounded
by other sex hormones. However, estrogens are not thought to be converted to testosterone in
men [37], and so do not meet the criteria of being a confounder [10]. Third, population stratification and canalization may affect MR analysis. However, the participants were restricted to
ethnic Chinese men with no known canalization, i.e., compensatory adaptation to genetic effects during development [10]. Fourth, MR is based on the assumption that the genetic instrument is associated with the exposure, is not associated with the outcome other than via the
exposure (no pleiotropy exists) and no confounders of the association of the genetic instrument
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with the outcomes exist [38]. We used SNPs from genes functionally relevant to testosterone.
The selected SNPs may affect systemic inflammation directly (pleiotropy) rather than via testosterone, however, no such evidence could be identified. The genetic prediction rule was not
associated with age, education or lifestyle (Table 1). Fifth, testosterone predicted from the genetic prediction rule is different from measured serum testosterone, as the genetic instrument
only explains a small proportion of the variance. Therefore, the estimates from MR are less precise (although less biased) than those from traditional regression [10]. MR studies require a
large sample size: approximately the usual sample size for exposure on outcome divided by the
R2 (here 0.04) between instrument and exposure [25]. The power of separate-sample MR is approximately equal to the power of traditional complete-data analysis in the traditional MR setting [28]. According to the formulas in the study of Freeman et al [25], for WBC, granulocyte
and lymphocyte counts, a sample size of ~4,200 had 0.8 power to detect a relatively small effect
size of 0.22, although the analysis of hsCRP, with a sample size of ~1,600 only had 0.8 power to
detect an effect size of 0.35. This is also consistent with simulation results from Pierce et al
[26]. The formulas provide a relatively simple and fast way to approximate the sample size required for a specific sample size to achieve a fixed power [25]. In GBCS, an effect size of 0.22 is
equivalent to a difference of about 0.37 109/L in WBC count, 0.34 109/L in granulocyte count,
and 0.14 109/L in lymphocyte count. Differences smaller than these are not expected to be clinically meaningful, although could make a difference on a population level. We used a weighted
genetic prediction rule instead of single SNP as instrument, reducing variability in MR estimation [39]. Replication with a stronger instrument in a larger sample or meta-analysis of MR
analyses is needed.

Conclusions
The study did not corroborate observations of an association of endogenous testosterone with
lower levels of markers of systemic inflammation and correspondingly any potentially protective effects of testosterone on complex chronic diseases via reducing low-grade
systemic inflammation.

Supporting Information
S1 Table. Genotypes of selected SNPs and genetic associations with log testosterone in the
young men.
(DOCX)
S1 Fig. Flow chart for SNP selection. For references identified in the figure, please see Appendix references in S1 File.
(TIF)
S1 File. Appendix references.
(DOCX)
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